📇 Rhumatologue · BOULOGNE BILLANCOURT · (92) · Libéral

MME AGNES LUPONIS

Pourquoi vous devez consulter ce praticien

3 raisons identifiées

Auteur de référence en rhumatologie
32 articles scientifiques publiés — un praticien à la pointe de la recherche
Disponibilité géographique
2 lieux d'exercice — choisissez celui qui vous arrange
Délais de RDV courts dans la région
136 rhumatos / 100 000 hab. — département bien doté

Rhumatologue

📍 BOULOGNE BILLANCOURT (92)LibéralRPPS 10000763556

✨ Génération du profil synthétique IA en cours…

Lieux de consultation(2)

CABINET DU DR AGNES LUPONIS
MDOP 98 ROUTE DE LA REINE, 92100 BOULOGNE BILLANCOURT
Activité de soin et de pharmacie
CABINET DU DR AGNES LUPONIS
CABINET MEDICAL 199 AVENUE MARGUERITE RENAUDIN, 92140 CLAMART
Activité de soin et de pharmacie

Tarifs & secteur de conventionnement

Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.

Top publications · les plus citées

Pulmonary Arterial Hypertension Incidence in Patients With Systemic Sclerosis Treated With Bosentan for Digital Ulcers: Evidence From the SPRING-SIR Registry

The Journal of rheumatology · 2025

📚 5 citations🎯 RCR 2.38

Lire l'abstract Crossref ↓

ObjectiveBosentan (BOS) is approved for treating pulmonary arterial hypertension (PAH) and preventing digital ulcers (DU) in systemic sclerosis (SSc). Our study aimed to evaluate whether BOS prescribed for DU could reduce the incidence of PAH in a large SSc cohort from the Systemic Sclerosis Progression Investigation (SPRING) registry.MethodsPatients with SSc from the SPRING registry, meeting 2013 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria with data on PAH onset, DU status, BOS exposure, and at least 1 year of follow-up between 2015 and 2020, and having no known PAH at baseline, were included. PAH was diagnosed with right heart catheterization during the follow-up, and its incidence rate (IR) was calculated. Kaplan-Meier curves were determined, and multivariate regression identified PAH risk factors.ResultsAmong 727 eligible patients with SSc, followed for a median of 2.0 years, 54 (7.4%) developed PAH (IR 3.71 per 100 patient-years [PYs]). Patients with DU who were never exposed to BOS had a higher incidence of PAH (IR 4.90 per 100 PYs) compared to those exposed to BOS, whose rates matched those without DU and who were never exposed to BOS. Risk factors independently associated with PAH development included DU (hazard ratio [HR] 1.86), age (HR 1.05), modified Rodnan skin score > 4 (HR 2.07), interstitial lung disease (HR 2.29), and acetylsalicylic acid treatment (HR 1.78).ConclusionIn our cohort, the presence of DU was confirmed as a leading risk factor for PAH development, and BOS use for DU prevention may reduce this risk. Only patients with DU who were not using BOS had an increased PAH incidence.

Safety and pharmacokinetics of SARS-CoV-2 DNA-encoded monoclonal antibodies in healthy adults: a phase 1 trial

Nature medicine · 2025

📚 4 citations🩺 Clinique🔓 Open Access📄 PDF gratuit ↗

First-line diagnostic tests to intercept primary heart involvement in systemic sclerosis: Clinical associations from the SPRING-SIR registry

European journal of clinical investigation · 2025

📚 3 citations🔓 Open Access📄 PDF gratuit ↗

Lire l'abstract Crossref ↓

Abstract Introduction Primary heart involvement (pHI) is an overlooked and poorly characterised complication of systemic sclerosis (SSc), associated with the risk of heart failure, arrhythmia and death. Despite consensus definition by the World Scleroderma Foundation/Heart Failure Association (WSF/HFA), diagnostic criteria and risk factors remain poorly elucidated. Methods Out of 1922 patients in the Italian national SPRING registry, we excluded those with potentially confounding conditions according to WSF/HFA, and those with incomplete ECG or echocardiographic assessment, resulting in 600 subjects with clearly defined parameters to intercept SSc‐pHI. Cross‐sectional and longitudinal analyses were performed to identify factors associated with pHI. Results ECG and/or echocardiographic signs of SSc‐pHI were identified in 25% of patients at enrollment and were associated with older age (OR 1.04; 95% CI 1.02–1.06), diffuse cutaneous SSc (OR 1.85; 95% CI 1.05–3.26) and intestinal symptoms (OR 1.79; 95% CI 1.03–3.08). Diastolic dysfunction (62%) and conduction disturbances (34%) were the most frequent phenotypes, while diffuse hypokinesia with reduced ejection fraction was the least common (3%). During follow‐up, new‐onset signs of pHI were observed in an additional 25% of patients, particularly in those with skeletal muscle involvement (HR 2.83; 95% CI 1.01–7.73). Conclusions pHI is a severe complication potentially affecting one‐quarter of patients with SSc. Early detection is crucial, particularly in those with diffuse skin fibrosis, muscular involvement and intestinal manifestations.

Cookies & analyse de trafic

MME AGNES LUPONIS

Pourquoi vous devez consulter ce praticien

Lieux de consultation(2)

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Top publications · les plus citées

Publications scientifiques (32) — classées par pathologie

Épidémiologie & registres10

Transversal5

Revue générale4

Pharmacovigilance3

Biomarqueurs / Auto-Ac2

Économie santé2

Qualité de vie / PROMs2

Sclérodermie2

Arthrite juvénile1

Gériatrie1

IA en rhumatologie1

Ostéoporose1

Revue / méta-analyse1

Vraie vie / RWE1

Partager cette fiche